



UNIVERSITI PUTRA MALAYSIA

**ANTI-MALARIAL ACTIVITY OF *GONIOTHALAMUS SCORTECHINII*
KING**

NOOR AZIAN BT. MD YUSUF

IB 2006 15



**ANTI-MALARIAL ACTIVITY OF *GONIOTHALAMUS*
SCORTECHINII KING**

By

NOOR AZIAN BT. MD YUSUF

**Thesis Submitted to the School of Graduates Studies, Universiti Putra
Malaysia, in Fulfilment of the Requirement for the Degree of Master of
Science**

February 2006



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in
fulfilment of the requirement for the Master of Science

**ANTI-MALARIAL ACTIVITY OF *GONIOTHALAMUS*
SCORTECHINII KING**

By

NOOR AZIAN BT. MD YUSUF

February 2006

Chairman: Associates Professor Khozirah Shaari, PhD

Faculty: Institute of Bioscience

Malaria remains the most devastating infectious parasitic disease, inflicting both death and economic losses on at least half the world population. Numerous attempts have been made to control the disease by using vector control measures or/and chemoprophylaxis, but they have had limited success. Immunoprophylaxis hold promises but effective vaccines are still not available. Presently, the most effective way of dealing with malaria is the administration of chemotherapeutic agents. Although drugs treatments of malaria are currently the best means of disease management, there is an urgent need for the development of effective anti-malarial drugs.

Earlier assessment of *Goniothalamus scortechinii* King showed to possess significant anti-malarial properties, *in vitro*. A phytochemical study of *G. schortechinii* King was thus carried out and has led to the isolation and

characterization of two compounds, goniotalamin and pinocembrine, from the bioactive chloroform fraction. Both compounds were assayed for anti-malarial activity using the pLDH method. Both exhibited anti-malarial activity against *P. falciparum* in different degrees, goniotalamin gave an IC₅₀ value of 4.0824 µg/ml while pinocembrine gave 19.308 µg/ml.

Goniotalamin was evaluated for its anti-malaria activity *in-vivo* using 4-Day Suppressive Test against *Plasmodium berghei* ANKA strain in Swiss Albino Mice. The 4DT was carried out by inoculating the clean mice with *P. berghei* ANKA strain and the infected mice were then treated orally and subcutaneously with goniotalamin. The suppression of parasite parasitemia and the ED₉₀ value of goniotalamin were determined. Control drug used in this study was Chloroquine. Results showed that goniotalamin when given orally at a dose of 90 and 120 mg/kg mice body weight, exhibited suppressions of *P. berghei* infection of 98% and 99.7%, respectively. Meanwhile, goniotalamin given subcutaneously at a dose 120 mg/kg mice body weight gave 90.5% suppression of *P. berghei* infection.

Ex vivo assay was carried out to investigate the effect of goniotalamin towards *P. falciparum in vitro* using the mouse serum treated with goniotalamin. This was done to prove that goniotalamin reaction toward *P. falciparum* should same as reaction towards *P. berghei* in *in vivo*

reaction. *Ex vivo* test was carried out using pLDH assay with serum of mice given goniothalamine orally and subcutaneously. A graph to determine the 90% inhibition of drugs-serum towards *P. falciparum* was plotted for each treated mice serum. Results showed the IS_{90} of mice serum given goniothalamine orally was ranging from 0.050 to 4.00 $\mu\text{g/ml}$, for subcutaneous route the IS_{90} was ranging from 0.009-4.750 $\mu\text{g/ml}$. A graph for estimating the length of time goniothalamine can remain in the blood was plotted. This gave the estimated time of goniothalamine both given orally and subcutaneously can remained a minimum of 6 hours in the blood.

In conclusion, goniothalamine does strongly inhibit *P. falciparum*, although it is not as potent as the standard drugs in use. More investigations such as drug combination, cytotoxicity, mechanism of action and toxicology studies, need to be carried out in order to determine its full potential as an anti-malarial.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia
sebagai memenuhi keperluan untuk ijazah Master Sains

**SIFAT ANTI-MALARIA DARIPADA *GONIOTHALAMUS*
SCORTECHINII KING**

Oleh

NOOR AZIAN BT. MD YUSUF

Februari 2006

Pengerusi: Profesor Madya Khozirah Shaari, PhD

Fakulti: Institut Biosains

Malaria masih merupakan masalah penyakit parasit berjangkit yang mengakibatkan kematian dan kerugian ekonomi sekurang-kurangnya kepada sesetengah daripada populasi dunia. Pelbagai tindakan telah dijalankan untuk mengawal penyakit ini dengan menggunakan pengawalan vektor penyakit atau/dan kemoprofilaksis, tetapi keberkesanannya adalah terbatas. Harapan tertumpu kepada Immunoprofilaksis tetapi vaksin yang berkesan masih belum didapati. Dewasa ini teknik yang paling berkesan dalam menangani malaria adalah penggunaan agen kemoterapeutik. Walaupun sekarang ini dadah untuk merawat malaria masih berkesan dalam pengurusan penyakit ini, tetapi ubat anti-malaria yang efektif masih perlu dibangunkan.

Penyelidikan fitoubatan secara *in-vitro* ke atas pokok *Goniothalamus scortechinii* King telah menunjukkan bahawa ia mempunyai khasiat sebagai

anti-malaria. Penyelidikan keatas fraksi kloroform yang bioaktif ini telah membawa kepada penemuan dan pengkelasan kompaun goniothalamine dan pinocembrine. Assai pLDH telah dijalankan ke atas kedua-dua kompaun ini bagi mengesan aktiviti anti-malaria, yang mana kedua-duanya telah menunjukkan darjah keupayaan yang berbeza sebagai anti-malaria apabila diuji secara *in-vitro* ke atas parasit *P. falciparum*. Nilai IC₅₀ untuk goniothalamine adalah 4.0824 µg/ml dan pinocembrine sebanyak 19.308 µg/ml.

Pengujian keatas aktiviti goniothalamine sebagai ubat anti-malaria secara *in vivo* telah dijalankan dengan kaedah "4 Day Suppressive Test" terhadap *P. berghei* strain ANKA di dalam mencit Swiss Albino. Khlorokuin telah digunakan sebagai kawalan dalam kajian ini. Keputusan telah menunjukkan bahawa pada dos 90 mg/kg dan 120 mg/kg yang diberikan secara oral, goniothalamine telah menindas peningkatan parasitemia parasit masing-masing sebanyak 98% dan 99.7%. goniothalamine apabila diberikan secara 'subcutaneous', telah menindas peningkatan parasitemia parasit sebanyak 90.5% apabila diberikan dos 120 mg/kg.

Kajian *ex vivo* pula dijalankan bagi melihat keberkesanan goniothalamine terhadap parasit *P. falciparum* secara *in-vitro* dengan menggunakan serum mencit yang telah diberikan goniothalamine. Ujian ini dijalankan bagi

membuktikan bahawa tindakbalas goniothalamine terhadap *P. falciparum* secara *in vitro* ini adalah sama kesannya apabila dijalankan secara *in vivo*. Goniothalamine telah diberikan secara oral dan 'subcutaneous', dan assai pLDH digunakan untuk menentukan 90% penyekatan serum-dadah terhadap peningkatan parasitemia *P. falciparum*. Graf untuk menentukur 90% penyekatan diplotkan bagi melihat tindakkan serum dadah ini terhadap *P. falciparum*. Keputusan menunjukkan IS₉₀ goniothalamine apabila diberikan goniothalamine secara oral telah menyekat peningkatan parasitemia pada kepekatan yang berbeza bermula daripada julat kepekatan 0.050 hingga 4.00 µg/ml, manakala untuk 'subcutaneous' IS₉₀ berjulat daripada 0.009- 4.750 µg/ml. Graf untuk melihat berapa lama serum-dadah boleh bertahan didalam dadah turut plotkan. Minimum masa untuk serum-dadah bertahan didalam darah dianggarkan selama 6 jam.

Kesimpulannya, goniothalamine telah menunjukkan keupayaannya untuk menyekat *P. falciparum* walaupun keupayaannya tidak sekuat standard dadah yang digunakan. Kajian lanjut perlu dilakukan seperti kombinasi dengan dadah lain, sitotoksiti, mekanisme tindakan, kajian keracunan (toxicology) demi menentukan keupayaan sebenarnya sebagai agen anti-malarial.

ACKNOWLEDGEMENTS

In the name of Allah S.W.T., the merciful and the beneficent

First of all, I would like to express my gratitude and thanks to all my supervisors, Prof. Madya Dr. Khozirah Shaari, Dr. Noor Rain Abdullah, Dr. Lokman Hakim Sulaiman and Prof. Madya Dr. Gwendoline ECL for all the guidance and advice throughout the course of the study.

I would like to take this opportunity to thank the Director of the Institute for Medical Research (IMR) for allowing me to conduct my study at the Institute. A warm and special thanks to all my friends at the Parasitology Lab, IDRC, namely Hj. Yusri Mohd Yusof, Dr. Shamilah Hisam, Gan CC, Malkith Kaur, Aishah mahmood, Mohd Azam Abu Bakar and Bioassay Lab, HMRC namely, Rohaya Chomel, Rosilawati Mohamad, Ahmad Napi, Khairudin Husin and not forgetting all friends for sharing the bad and good times together and supporting me throughout this study. I also would like to express my special thanks to the staff of Institute of Bioscience and Graduate school , UPM for their assistant in completing this study.

And last but not least to my big beloved family, Allahyarham Md Yusuf Hj Awang and Allahyarhamah Rubiah Ismail, my beloved and caring stepmother Rokiah Md Noor, my Sisters and brothers, Umi Kalsum, Umi Sofian, Md Amran, Noriza, Noor Zila, Noor Zurawati, Noor Ziana, Nurul Ashikin, Mohd Amirul Azdi, Azrul Hisyam, Mohd Fikry Affendi and in-laws, Suhaimi, Razif, Rohaida, Dunian, Amir, Rosli and Azmir for their moral and financial support.

Noor Azian Bt Md Yusuf

Sik, Kedah

February 2006

I certify that an Examination Committee met on 24 February 2006 to conduct the final examination of Noor Azian Bt. Md Yusuf on her Master of Science thesis entitled “Anti-malarial Activity of *Goniothalamus Scortechinii* King” in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the candidate be awarded the relevant degree. Members of the Examination Committee are as follows:

Irmawati Ramli, PhD

Lecturer
Faculty of Science
Universiti Putra Malaysia
(Chairman)

Abdul Manaf Ali, PhD

Professor
Faculty of Biotechnology and Biomolecular Sciences
Universiti Putra Malaysia
(Internal Examiner)

Mohd Aspollah Sukari, PhD

Associates Professor
Faculty of Science
Universiti Putra Malaysia
(Internal Examiner)

Zainal Abidin Abu Hasan, PhD

Professor
Faculty of Life Science
Universiti Kebangsaan Malaysia
(External Examiner)

Hasanah Mohd Ghazali, PhD
Professor/Deputy Dean
School of Graduates Studies
Universiti Putra Malaysia

Date:

This thesis submitted to the Senate of University Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The member of the Supervisory Committee are as follows:

Khozirah Shaari, PhD

Associate Professor
Institute of Bioscience
Universiti Putra Malaysia
(Chairman)

Noor Rain Abdullah, PhD

Bioassay Units
Herbal Medicine Research Centre
Institute for Medical Research
(Member)

Lokman Hakim Sulaiman, PhD

Medical Consultant
Infectious Disease Research Centre
Institute for Medical Research
(Member)

Gwendoline EE Cheng Lian, PhD

Associates Professor
Faculty of Science
Universiti Putra Malaysia
(Member)

AINI IDERIS, PhD
Professor/Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citation which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institutions.

NOOR AZIAN BT MD YUSUF

Date: 10 May 2006

TABLE OF CONTENTS

	PAGE
ABSTRACT	ii
ABSTRAK	v
ACKNOWLEDGMENTS	viii
APPROVAL	x
DECLARATION	xii
LIST OF TABLES	xv
LIST OF FIGURES	xvi
LIST OF ABBREVIATION	xviii
CHAPTER	
I INTRODUCTION	
Malaria	1
Epidemiology	2
The need for new anti-malarial drugs	6
II LITERATURE REVIEW	
Morphology of the malaria parasite	10
Human malaria parasite: <i>Plasmodium falciparum</i>	11
Murine Malaria Parasite: <i>Plasmodium berghei</i>	12
The Life Cycle of Malaria Parasite:	
<i>P. falciparum</i>	14
<i>P. berghei</i>	15
Mechanism of malaria infection	16
Clinical malaria	
Clinical sign and symptom	20
Severe malaria	20
Hypnozoite and relapse and recrudescence	21
Chemotherapy	
Drug in used	22
Mechanism of drug action	25
Definition and classification of drugs resistance	26
Challenges in chemotherapy	29
The genus <i>Goniothalamus</i> Hook.f. & Thomson	
Distribution and botany	33
Medicinal uses	34
Chemical constituents of <i>Goniothalamus spp.</i>	35
<i>Goniothalamus scoetechinii</i> King	42
Previous work on <i>G. scoetechinii</i> King	43



III	METHODOLOGY	
	General:	
	Instrumentation	45
	Chromatography	45
	Plant material:	47
	Preparation and extraction of plant material	48
	Isolation of compound	49
	Physical and spectral properties of goniotalamin (G1)	50
	Physical and spectral properties of pinocembrine (G2)	50
	Resourcing of goniotalamin (G1) from <i>G. andersonii</i> for <i>in vivo</i> and <i>ex vivo</i> assay	51
	Parasite Lactate Dehydrogenase (pLDH) assay	52
	Malstat test	54
	Determination of IC ₅₀ values	55
	Determination of blood schizonticidal activity <i>in vivo</i> and <i>ex vivo</i>	55
	<i>In vivo</i> assay	56
	Infection of donor mice with <i>P. berghei</i> and calculation of % parasitemia	57
	Preparation of test and standard drugs	58
	Preliminary four day suppressive test (Pre-4DT)	58
	Full four day suppressive test (4DT)	60
	<i>Ex vivo</i> assay	62
	Calculation of IS50 values	64
IV	RESULTS AND DISCUSSION	
	Extraction and isolation of compound from crude chloroform extract of <i>Goniotalamus scortechinii</i> King	66
	Characterization of G1 as goniotalamin	66
	Characterization of G2 as pinocembrin	78
	Inhibition of pLDH activity by test compound	95
	<i>In-vivo</i> evaluation of anti-malarial effect of goniotalamin	96
	<i>Ex-vivo</i> evaluation of anti-malarial effect of goniotalamin	100
V	SUMMARY AND CONCLUSION	104
	REFERENCES	106
	APPENDICES	112
	BIODATA OF THE AUTHOR	128

LIST OF TABLES

Table		Page
1.1	Malarial cases in Malaysia according to the infecting species for the year 2001 and 2002	5
2.1	Available anti-malarial drugs	23
3.1	Experimental design for 4DT	62
4.1	^1H - ^{13}C correlation based on HMBC experiment on G1	69
4.2	^1H - ^{13}C correlation based on HMBC experiment on G1	81
4.3	IS ₉₀ of mice given goniothalamine orally	102
4.4	IS ₉₀ of mice given goniothalamine subcutaneously	102
D.1	ED ₅₀ and ED ₉₀ of several standard compounds (used as references to validate the blood schizonticidal activity obtained in the <i>in vivo</i> study)	123

LIST OF FIGURES

Figure		Page
1.1	Regions of the world at risk of malaria Infections	4
2.1	The life cycles of the malaria parasite	19
2.2	Classification of sensitivity and resistance to ant-malaria	28
2.3	<i>Goniothalamus scortechinii</i> King	44
3.1	Treatment regime of mice serum sample for <i>ex-vivo</i> assay	65
4.1	EIMS Spectrum of G1; $C_{13}H_{12}O_2$	70
4.2	1H NMR spectrum for G1	71
4.3	^{13}C NMR spectrum for G1	72
4.4	COSY spectrum for G1	73
4.5	HSQC spectrum of G1	74
4.6a-c	Summarized of HMBC experiment on G1	75
4.7	Full assignment and selected HMBC correlation of goniothalamine	78
4.8	EIMS Spectrum of G2; $C_{15}H_{11}O_4$	82
4.9a-b	1H NMR Spectrum of G2	83
4.10	COSY spectrum of G2	85
4.11	^{13}C NMR spectrum of G2	86
4.12a-b	HSQC Spectrum of G2	87
4.13a-f	HMBC Spectrum of G2	89
4.14	The ED_{90} of goniothalamine (G1) given orally	95



4.15	The ED ₉₀ of goniothalamine (G1) given Subcutaneously	98
4.16	Blood schizonticidal activity of parasite in mouse after treatment with chloroquine (CQ)	98
4.17	Blood schizonticidal activity of parasite in mouse after treatment with goniothalamine (G1)	99
4.18	Availability of mice drug-serum in blood when given goniothalamine orally	99
4.19	Availability of mice drug-serum in blood when given goniothalamine orally	103
4.20	Availability of mice drug-serum in blood when given goniothalamine subcutaneously	103
D.1	Graph of Probit Analysis for 4-DT carried out using <i>P. yoelli</i> N strain, standard drug Na artesunate, via oral route.	122
E.1	% Parasitemia in blood serum of Mouse A (Oral Route)	124
E.2	% Parasitemia in blood serum of Mouse B (Oral Route)	124
E.3	% Parasitemia in blood serum of Mouse C (Oral Route)	125
E.4	% Parasitemia in blood serum of Mouse D (Oral Route)	125
E.5	% Parasitemia in blood serum of Mouse A (SC Route)	126
E.6	% Parasitemia in blood serum of Mouse B (SC Route)	126
E.7	% Parasitemia in blood serum of Mouse C (SC Route)	127
E.8	% Parasitemia in blood serum of Mouse D (SC Route)	127



LIST OF ABBREVIATION

APAD	Analog 3 acetyl pyridine dinucleotide
BC	Before Century
BH	Beta- haematin
CQ	Chloroquine
CM	Culture Medium
CO ₂	Carbon dioxide
COSY	Correlated Spectroscopy
DNA	Deoksinukleik Acid
DMSO	Dimethyl-sulphate
dHFR	Dehydrofolate Reductase
dHPS	Dehydropteroate Synthase
ED ₉₀	Effective Dose at 90%
ELISA	Enzyme Linked Immunosorbent Assay
EIR	Erythrocyte Infection Rate
EIMS	Electrospray Ionization Mass Spectrometry
FPIX	Free ferriprotoporphyrin IX hydroxide
g	Gram
HMRC	Herbal Medicine Research Centre
HMQC	Heteronuclear Multiple Quantum Correlation
HSQC	Heteronuclear Single Quantum Correlation
HMBC	Heteronuclear Multiple Bond Correlation
Hb	Hemoglobin



HS	Human Serum
IRBC	Infected Red Blood Cell
IMR	Institute for Medical Research
IC ₅₀	Inhibition Concentration at 50%
IS ₅₀	Inhibition of Serum Concentration at 50%
ICR	Swiss Albino Mice
IV	Intra-veneous
Kb	Kilo-base
LDH	Lactate Dehydrogenase
MS	Mass Spectroscopy
MQ	Milipore Quality water
ml	Mili-liter
mg/kg	Mili-gram per kilo-gram
NBT	Nitroblue Tetrozolum
NMR	Nuclear Magnetic Resonance
NaOH	Natrium Hydroxide
NaCl	Natrium Chloride
N ₂	Nitrogen
O	Oral Route
O ₂	Oxygen
PRBC	Peripheral Red Blood Cell
PABA	p-amino Benzoic Acid
PBS	Phosphate Buffered Saline

PES	Phenazine ethhiosulphate
Pre-4DT	Preliminary Four Day Test
pLDH	Parasite Lactate Dehydrogenase
RBCs	Red Blood Cells
SC	Subcutaneous Route
SP	Sulfadoxine/ Phyrimethamin
TLC	Thin Layer Chromatografi
WHO	World Health Organisation
⁰ C	Degrees Celcius
μl	Micro-liter
4DT	Four Day Test
λ _{max}	In UV spectroscopy, the wavelength at which maximum absorption occurs

CHAPTER I

INTRODUCTION

Malaria

Malaria continues to exact a substantial toll of human life and sufferings, particularly in the tropic and sub-tropic regions of the world. Human malaria has been recognized since the earliest period of man's recorded history, and the discovery of mosquitoes trapped in amber suggests its prevalence in pre-historic times. A variety of names have been used to describe the disease such as the shakes, March, Roman, jungle, intermittent fever and ague chills. It was earlier thought that there was an etiological relationship between swamps and this fever. The name malaria is a misnomer and has originated from the Italian words *mala* (bad) and *aryia* (air) since in earlier days it was believed to be caused by breathing bad air (Ichpujani and Bathia, 1998 and Smyth, 1976).

Malaria is caused by single celled protozoa of the genus *Plasmodium*. *Plasmodium* does not only infect man but also apes, monkeys, birds and other vertebrate hosts. Four species of *Plasmodium* pathogenic to man are *P. falciparum* (malignant tertian or *falciparum* malaria), *P. vivax*



(benign tertian or *vivax* malaria, 48 hours cycles), *P. malariae* (quartan malaria, 72 hours cycles) and *P. ovale* (mild tertian or mild malaria). Species parasitic to birds are *P. gallinaceum* (chicken), *P. elongatum*, *P. reticulum* and *P. cathemerium*. Simian malaria includes *P. knowlesi*, *P. cynomolgi*, *P. inui*, *P. simium* and *P. lophure*, while species parasitic to murine rodents are *P. bergeri*, *P. vinckei*, *P. chabaudi* and *P. yoelii* (Ichpujani and Bathia, 1998; LaPage, 1963; Rosenthal, 2001).

Epidemiology

In 1955, WHO launched a program to eradicate malaria. This effort produced some important successes, but, for the most part, it has been a major disappointment. Indeed, over recent decades, morbidity and mortality caused by malaria have increased in many parts of the world with a large proportion of the world's population remaining at risk of contracting this disease (Fig. 1.1). Hundred of millions of clinical episodes of malaria occur each year and it was estimated that 1.5-2.7 million deaths resulted from these infections. Numerous factors contribute to the persistence of the malaria problem and annually these include, among others:-

- efforts to control mosquito vectors, which were quite successful in some areas many years ago, have been limited by financial constraints and insecticide resistance
- programs to treat and control malaria, especially in highly vulnerable young children and pregnant women, are limited by poverty in most endemic regions
- despite many efforts, an effective malaria vaccine is not yet available and is unlikely to be available to those most at need in the near future
- malarial parasites have consistently demonstrated the ability to develop resistance to available drugs
- although great progress have been made in our understanding of malaria in recent years, our ability to develop new strategies to control the disease remain significantly limited by an incomplete understanding of the biology of the parasite and of the host's response to parasite infection (Rosenthal, 2001)

Malaysia is no exception from the risk of malaria. Up to the days of the Malacca Sultanate, settlements had to be largely restricted to river mouths to avoid risks of malarial infections, thus curtailing population growth. In 1829, forty years after Penang Island was first occupied, one third of the deaths were caused by malaria (Lim, 2001).

Table 1.1 shows the number of malarial cases reported in 2001 and 2002 according to the infecting species in Malaysia. In 2001, *P. falciparum* and *P. vivax* account for just below 50% of malarial cases but in 2002, the cases increased to more than 50% for *P. falciparum* and 50% for *P. vivax*. In Sabah, malarial cases for 2001 were 54.87% and this increased to 64.2% in 2002. Malarial cases in Sarawak in 2001 and 2002 remained under 20% (MOH Annual Report, 2002).




Figure 1.1: Regions of the world at risk of malarial infections.

(The shrinking range of malaria is depicted by overlaying WHO maps for malaria risk for the year 1946 (yellow), 1966 (brown) and 1994 (red).